丰倍生物IPO获上交所上市委会议通过

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its initial public offering (IPO) on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for various projects and working capital [1] Financial Performance - The company reported revenues of 1.709 billion yuan in 2022, 1.728 billion yuan in 2023, and projected 1.949 billion yuan in 2024, indicating a growth trend [1] - Net profits for the same years were 133 million yuan in 2022, 130 million yuan in 2023, and a forecast of 124 million yuan in 2024, showing a slight decline [1] - Basic earnings per share were 1.26 yuan in 2022, 1.21 yuan in 2023, and are expected to be 1.15 yuan in 2024, reflecting a downward trend [1] Key Financial Indicators - Revenue for 2024 is projected at 1.948 billion yuan, up from 1.728 billion yuan in 2023 and 1.709 billion yuan in 2022 [1] - The net profit attributable to shareholders is expected to be 123.82 million yuan in 2024, down from 129.71 million yuan in 2023 and 133.35 million yuan in 2022 [1] - The weighted average return on equity is forecasted to be 17.91% in 2024, a decrease from 22.43% in 2023 and 30.57% in 2022 [1]